Evofem Biosciences is a biotechnology business based in the US. Evofem Biosciences shares (EVFM) are listed on the OTCQB and all prices are listed in US Dollars. Evofem Biosciences employs 37 staff and has a trailing 12-month revenue of around $16 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.01 |
|---|---|
| 52-week range | $0.01 - $0.68 |
| 50-day moving average | $0.01 |
| 200-day moving average | $0.04 |
| Wall St. target price | $225.00 |
| PE ratio | 0.006 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $1.74 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.01 from 2024-07-24
| 1 week (2024-07-19) | -9.09% |
|---|---|
| 1 month (2024-06-26) | 0.01 |
| 3 months (2024-04-26) | -41.18% |
| 6 months (2024-01-26) | -71.43% |
| 1 year (2023-07-26) | -97.65% |
|---|---|
| 2 years (2022-07-26) | -98.79% |
| 3 years (2021-07-26) | 0.858 |
| 5 years (2019-07-26) | 4.99 |
Valuing Evofem Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Evofem Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Evofem Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Evofem Biosciences shares trade at around 0x recent earnings.
| Revenue TTM | $16 million |
|---|---|
| Gross profit TTM | $12.4 million |
| Return on assets TTM | -62.45% |
| Return on equity TTM | -387.27% |
| Profit margin | 315.54% |
| Book value | $-1.45 |
| Market Capitalization | $651,634 |
TTM: trailing 12 months
We're not expecting Evofem Biosciences to pay a dividend over the next 12 months.
Evofem Biosciences's shares were split on a 1:125 basis on 17 May 2023. So if you had owned 125 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Evofem Biosciences shares – just the quantity. However, indirectly, the new 12400% higher share price could have impacted the market appetite for Evofem Biosciences shares which in turn could have impacted Evofem Biosciences's share price.
Over the last 12 months, Evofem Biosciences's shares have ranged in value from as little as $0.006 up to $0.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while Evofem Biosciences's is -0.738. This would suggest that Evofem Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Evofem Biosciences has bucked the trend.
Evofem Biosciences, Inc. , a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California. .
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.